Education
About Us
Working with TipRanks
Follow Us
Botanix Pharmaceuticals Limited (AU:BOT)
ASX:BOT
BOT Stock Chart & Stats
AU$0.04
>-AU$0.01(-1.09%)
At close: 4:00 PM EST
AU$0.04
>-AU$0.01(-1.09%)
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.49
Previous CloseN/A
Volume8.15M
Average Volume (3M)8.47M
Market Cap
AU$95.38M
Enterprise ValueAU$94.44M
Total Cash (Recent Filing)AU$31.61M
Total Debt (Recent Filing)AU$30.67M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Aug 27, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding2,218,097,400
10 Day Avg. Volume7,344,780
30 Day Avg. Volume8,473,310
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)7.26
Price to Sales (P/S)101.98
P/FCF Ratio-7.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.62Price Target Upside1450.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.02
Revenue Forecast (FY)AU$38.10M
Bulls Say, Bears Say
Bulls Say
Commercial ExpansionExpanded U.S. sales force and scaling of the commercial footprint are driving strong prescription momentum and broader prescriber awareness, which could translate into sustained revenue growth as market penetration increases.
Fulfillment EfficiencyThe Botanix Fulfillment Platform's substantially higher prescription fill rate versus peers improves conversion of prescriptions into paid sales and supports more stable gross-to-net outcomes as volume grows.
Supply Chain And MarginsAddition of an alternative API supplier reduces single-source dependency and is expected to lower manufacturing costs, creating potential for margin expansion.
Bears Say
Capital Structure RiskReliance on external financing for working capital and manufacturing components raises capital-raising risk, which could amplify volatility if operational performance falls short of expectations.
Share OverhangThe share issuance associated with the financing may create an overhang that increases selling pressure and constrains stock appreciation.
ValuationAnalyst lowered the price target due to dilution from the financing, indicating a reduced valuation per share that can limit upside for investors.
Botanix Pharmaceuticals Limited News
BOT FAQ
What was Botanix Pharmaceuticals Limited’s price range in the past 12 months?
Botanix Pharmaceuticals Limited lowest share price was AU$0.04 and its highest was AU$0.48 in the past 12 months.
What is Botanix Pharmaceuticals Limited’s market cap?
Botanix Pharmaceuticals Limited’s market cap is AU$95.38M.
When is Botanix Pharmaceuticals Limited’s upcoming earnings report date?
Botanix Pharmaceuticals Limited’s upcoming earnings report date is Aug 27, 2026 which is in 157 days.
How were Botanix Pharmaceuticals Limited’s earnings last quarter?
Botanix Pharmaceuticals Limited released its earnings results on Feb 27, 2026. The company reported -AU$0.017 earnings per share for the quarter, missing the consensus estimate of -AU$0.01 by -AU$0.007.
Is Botanix Pharmaceuticals Limited overvalued?
According to Wall Street analysts Botanix Pharmaceuticals Limited’s price is currently Undervalued.
Does Botanix Pharmaceuticals Limited pay dividends?
Botanix Pharmaceuticals Limited does not currently pay dividends.
What is Botanix Pharmaceuticals Limited’s EPS estimate?
Botanix Pharmaceuticals Limited’s EPS estimate is -0.01.
How many shares outstanding does Botanix Pharmaceuticals Limited have?
Botanix Pharmaceuticals Limited has 2,218,097,400 shares outstanding.
What happened to Botanix Pharmaceuticals Limited’s price movement after its last earnings report?
Botanix Pharmaceuticals Limited reported an EPS of -AU$0.017 in its last earnings report, missing expectations of -AU$0.01. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Botanix Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in AU:BOT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Botanix Pharmaceuticals Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.62 (1450.00% Upside)
AU$0.62 (1450.00% Upside)
Blogger Sentiment
Bullish
AU:BOT Sentiment 95%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.57%
12-Months-Change
Fundamentals
Return on Equity
-131.13%
Trailing 12-Months
Asset Growth
-0.88%
Trailing 12-Months
Company Description
Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase IIb clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. The company was incorporated in 1984 and is based in Leederville, Australia.
BOT Stock 12 Month Forecast
Average Price Target
AU$0.62
▲(1450.00% Upside)
Technical Analysis
Options Prices
Currently, No data available
---